Adage Capital Partners
MRNS

Adage Capital Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Adage Capital Partners’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,331,250
Closed -$21.1M – 967
2024
Q1 		$21.1M Sell
2,331,250
-250,000
-10% -$2.43M 0.04% 437
2023
Q4 		$28.1M Sell
2,581,250
-323,226
-11% -$2.42M 0.06% 336
2023
Q3 		$23.4M Buy
2,904,476
+173,226
+6% +$1.44M 0.05% 347
2023
Q2 		$29.7M Buy
2,731,250
+696,750
+34% +$5.97M 0.06% 302
2023
Q1 		$14M Sell
2,034,500
-18,000
-0.9% -$113K 0.03% 532
2022
Q4 		$8.17M Buy
2,052,500
+815,000
+66% +$4.01M 0.02% 684
2022
Q3 		$8.23M Sell
1,237,500
-25,000
-2% -$154K 0.02% 688
2022
Q2 		$6.11M Hold
1,262,500
– – 0.01% 777
2022
Q1 		$11.8M Hold
1,262,500
– – 0.02% 650
2021
Q4 		$15M Hold
1,262,500
– – 0.03% 582
2021
Q3 		$14.4M Hold
1,262,500
– – 0.03% 584
2021
Q2 		$22.6M Sell
1,262,500
-200,000
-14% -$3.22M 0.04% 418
2021
Q1 		$22.6M Hold
1,462,500
– – 0.05% 407
2020
Q4 		$17.8M Hold
1,462,500
– – 0.04% 440
2020
Q3 		$18.8M Sell
1,462,500
-112,500
-7% -$971K 0.05% 393
2020
Q2 		$16M Buy
1,575,000
+375,000
+31% +$3.45M 0.04% 439
2020
Q1 		$9.74M Hold
1,200,000
– – 0.03% 474
2019
Q4 		$10.4M Buy
+1,200,000
New +$6.73M 0.03% 531
2018
Q1 		– Sell
-141,750
Closed -$4.63M – 773
2017
Q4 		$4.63M Sell
141,750
-8,250
-6% -$222K 0.01% 633
2017
Q3 		$3.52M Buy
+150,000
New +$1.68M 0.01% 646

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners's MRNS Position: Q2 2024 in Review

Adage Capital Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 2,331,250 shares — an estimated $21.1M sold.

Adage Capital Partners first reported a position in MRNS in Q3 2017 and held it in 20 quarters. The position peaked at $29.7M in Q2 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Adage Capital Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Adage Capital Partners sold 2,331,250 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $21.1M.
  • Adage Capital Partners first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 20 quarters.
  • Adage Capital Partners's Marinus Pharmaceuticals, Inc position peaked at $29.7M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Adage Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.